TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7880665

Group type: EXPERIMENTAL
Intervention: Convective warming using BairHugger and Warm Touch blankets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BairHugger 500 power unit set at medium setting of 38 degrees C
Number of subjects: 0
Study: 2833881

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31597622

Group type: EXPERIMENTAL
Intervention: Melatonin (2 x 5mg/day)
Number of subjects: 60
Study: 30115054

Group type: EXPERIMENTAL
Intervention: Daily Physical Activity (DPA) program consisting of 20 minutes of teacher-led DPA for 20 consecutive weeks
Number of subjects: 362

Group type: COMPARATOR
Intervention: Control group (usual practices)
Number of subjects: 362
Study: 26890552

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA)
Number of subjects: 1789

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 1789
Study: 25742320

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention (customised, interactive, automated voice reminders sent weekly)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 631

Group type: EXPERIMENTAL
Intervention: Mobile phone intervention
Number of subjects: 631
Study: 22943559

Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (7-day exposure)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (single exposure)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Rectal TFV 1% gel (single and 7-day exposure)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral TDF (300 mg single exposure)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Hydroxyethyl cellulose (HEC) placebo gel
Number of subjects: 18
Study: 16193473

Group type: EXPERIMENTAL
Intervention: Celiac patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 11958408

Group type: EXPERIMENTAL
Intervention: Bioactive glass grafting material used in dental implants
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bioactive glass grafting material
Number of subjects: 17
Study: 10418907

Group type: EXPERIMENTAL
Intervention: DTwP//PRP‐T vaccine (group A, N = 85)
Number of subjects: 168

Group type: COMPARATOR
Intervention: DTwP//Placebo vaccine (group B, N = 83)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: DT booster dose at age 5 years (subgroup A1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: DT booster dose at age 5 years (subgroup B1)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Hib polysaccharide (PRP) vaccine (subgroups A2 and B2)
Number of subjects: 168
Study: 7477984

Group type: EXPERIMENTAL
Intervention: Standardized measures of functional capacity and neuropsychological performance
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CT indices of striatal atrophy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: CT index of frontal atrophy
Number of subjects: 60
Study: 1705089

Group type: EXPERIMENTAL
Intervention: Thrombin infusion via a four-way balloon catheter (5,000 U in 5 ml of saline)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Conventional three-way balloon catheter (control group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Thrombin infusion group
Number of subjects: 89
Study: 7287324

Group type: EXPERIMENTAL
Intervention: Vertex-negative external current
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Vertex-positive external current
Number of subjects: 32
Study: 30870477

Group type: EXPERIMENTAL
Intervention: Segmentation algorithm for lumen contours and stent struts in OCT images
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Quality assessment algorithm for OCT pullbacks
Number of subjects: 23
Study: 28424088

Group type: EXPERIMENTAL
Intervention: Intervention alongside usual care
Number of subjects: 96

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 96
Study: 26687697

Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (2400 mg/d; DHA: 1450 mg, EPA: 400 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 23311957

Group type: EXPERIMENTAL
Intervention: IM olanzapine 10 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 90
Study: 21658014

Group type: EXPERIMENTAL
Intervention: PEEP (10 cmH(2)O)
Number of subjects: 32

Group type: COMPARATOR
Intervention: ZEEP (0 cmH(2)O)
Number of subjects: 32
Study: 18300861

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 10

Group type: COMPARATOR
Intervention: Verapamil (control)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 10
Study: 15831596

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 395
Study: 12548300

Group type: EXPERIMENTAL
Intervention: Mild upper respiratory infection
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Acute pneumonia
Number of subjects: 138

Group type: COMPARATOR
Intervention: Healthy non-anemic children (control group)
Number of subjects: 138
Study: 11205300

Group type: EXPERIMENTAL
Intervention: Amifostine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (historical)
Number of subjects: 14
Study: 9322777

Group type: EXPERIMENTAL
Intervention: RU486 (mifepristone) and prostaglandin analogues
Number of subjects: 41
Study: 7968336

Group type: EXPERIMENTAL
Intervention: Hand mask technique
Number of subjects: 60

Group type: COMPARATOR
Intervention: Manual ventilation through a face mask
Number of subjects: 60
Study: 3777553

Group type: EXPERIMENTAL
Intervention: Intranasal nifedipine (10 mg)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem (0.3 mg X kg‐1 followed by continuous infusion of 3 micrograms X kg‐1 X min‐1)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (no preventive treatment)
Number of subjects: 63
Study: 28823192

Group type: EXPERIMENTAL
Intervention: Manual removal of the placenta
Number of subjects: 574

Group type: COMPARATOR
Intervention: Spontaneous delivery of the placenta
Number of subjects: 574
Study: 26902281

Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg/day) plus Risperidone (up to 6 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo plus Risperidone (up to 6 mg/day)
Number of subjects: 64
Study: 24979828

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23326961

Group type: EXPERIMENTAL
Intervention: Peer education
Number of subjects: 80

Group type: COMPARATOR
Intervention: Current education
Number of subjects: 80
Study: 20546155

Group type: EXPERIMENTAL
Intervention: Surgical pulmonary veins isolation (SURG)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Radiofrequency pulmonary veins isolation (RF)
Number of subjects: 22
Study: 19013980

Group type: EXPERIMENTAL
Intervention: Single dose mitomycin C (MMC) administered to 49 patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: No mitomycin C administered to 51 patients
Number of subjects: 100
Study: 16192524

Group type: EXPERIMENTAL
Intervention: Touchscreen desktop computer (kiosk)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Hand-held computer (PDA)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Paper questionnaire
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: All study arms (including kiosk, PDA, and paper)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Computerized arms (kiosk and PDA)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Paper arm
Number of subjects: 366
Study: 12866362

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 mg/day for 3 months)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 26
Study: 10440415

Group type: EXPERIMENTAL
Intervention: Clopidogrel 100 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel 200 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel 400 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel (400 mg, capsules and tablets)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Clopidogrel 400 mg and 600 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 8818742

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 52
Study: 1899364

Group type: EXPERIMENTAL
Intervention: 150 mg rt-PA with heparin and aspirin
Number of subjects: 908

Group type: COMPARATOR
Intervention: 100 mg rt-PA with heparin and aspirin
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Patients with any history of neurological disease
Number of subjects: 908

Group type: EXPERIMENTAL
Intervention: Patients with intracerebral hemorrhage
Number of subjects: 908
Study: 7052115

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) vaginal tablet (3 mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amniotomy and intravenous oxytocin
Number of subjects: 100
Study: 30477911

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) plus masking therapy and sound treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Masking therapy and sound treatment
Number of subjects: 100
Study: 27730478

Group type: EXPERIMENTAL
Intervention: Action Observation Training (AOT-G)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (C-G)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 42
Study: 25833772

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet with 3-4 dairy product servings (2092 kJ/d reduction) over 12 weeks
Number of subjects: 67
Study: 24655622

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50mg/day
Number of subjects: 628

Group type: COMPARATOR
Intervention: Fluoxetine 20-40mg/day
Number of subjects: 628
Study: 22467985

Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (PAP adherence with telemedicine)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (PAP adherence without telemedicine)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (PAP adherence on days used)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard care (PAP adherence on days used)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Telemedicine monitoring system (technician time)
Number of subjects: 75
Study: 19534021

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/d for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pre-existing treatments without spironolactone
Number of subjects: 0
Study: 17519271

Group type: EXPERIMENTAL
Intervention: Oral leflunomide (LEF) 30 mg/day
Number of subjects: 54

Group type: COMPARATOR
Intervention: Oral methotrexate (MTX) starting with 7.5 mg/week reaching 20 mg/week after 8 weeks
Number of subjects: 54
Study: 15221659

Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin/metronidazole plus chlorhexidine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Mechanical debridement alone
Number of subjects: 35
Study: 11293554

Group type: EXPERIMENTAL
Intervention: Adapalene gel (0.1%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adapalene cream (0.1%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Erythromycin (4%)/tretinoin (0.025%) solution
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Erythromycin (4%)/tretinoin (0.025%) gel
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Erythromycin (2%)/isotretinoin (0.05%) gel
Number of subjects: 36

Group type: COMPARATOR
Intervention: White petrolatum (negative control)
Number of subjects: 36
Study: 9711101

Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive exercise test result
Number of subjects: 0
Study: 7697479

Group type: EXPERIMENTAL
Intervention: Intranasal ragweed challenge (doses 10, 100, and 1000 PNU)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 18
Study: 2745339

Group type: EXPERIMENTAL
Intervention: 0.35 ppm O3
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 0.20 ppm O3
Number of subjects: 15

Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 15
Study: 821168

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium Cromoglycate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Choline Theophyllinate
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Atropine Methonitrate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31904863

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 209
Study: 29308962

Group type: EXPERIMENTAL
Intervention: Kinesio® taping
Number of subjects: 39
Study: 26360147

Group type: EXPERIMENTAL
Intervention: Cervical positive sagittal malalignment (CPSM)
Number of subjects: 182

Group type: COMPARATOR
Intervention: No baseline cervical deformity (NONE)
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Cervical kyphosis (CK)
Number of subjects: 182
Study: 24252717

Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin administration
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 22077070

Group type: EXPERIMENTAL
Intervention: Baseline 25(OH)D levels
Number of subjects: 973

Group type: COMPARATOR
Intervention: Daily azithromycin
Number of subjects: 973
Study: 20033726

Group type: EXPERIMENTAL
Intervention: Absorbable sutures (AS) with tacks
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Double crown (DC) with tacks
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Nonabsorbable sutures (NS) with tacks
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: QoL survey
Number of subjects: 199
Study: 17188409

Group type: EXPERIMENTAL
Intervention: Amoxicillin 2g combined with clavulanic acid, orally daily for 5 days postoperatively
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Amoxicillin 2g combined with clavulanic acid, starting 5 days before the operation
Number of subjects: 150

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 150
Study: 15654549

Group type: EXPERIMENTAL
Intervention: 44 mcg subcutaneously three times weekly (tiw)
Number of subjects: 677

Group type: COMPARATOR
Intervention: 30 mcg intramuscularly once weekly (qw)
Number of subjects: 677
Study: 11238511

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (400-600 IU/day) and calcium (500 mg/day)
Number of subjects: 7564
Study: 9550248

Group type: EXPERIMENTAL
Intervention: Medication management plus marital intervention for 11 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication management plus marital intervention
Number of subjects: 0
Study: 7942680

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg each morning
Number of subjects: 27
Study: 3227297

Group type: EXPERIMENTAL
Intervention: 80 mg oral propranolol twice daily for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo twice daily for 7 days
Number of subjects: 20
Study: 2232492

Group type: EXPERIMENTAL
Intervention: Sham hemodialysis with regenerated cellulose membrane (Group CU)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sham hemodialysis with indomethacin administration (Group CU-IND)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham hemodialysis with polyacrylonitrile membrane (Group AN)
Number of subjects: 24
Study: 5350103

Group type: EXPERIMENTAL
Intervention: Glycopyrronium
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1-hyoscyamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Inert tablets (placebo)
Number of subjects: 90
Study: 31874890

Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention with tailored advice only
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Web-based physical activity intervention with tailored advice and Fitbit
Number of subjects: 300

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 300
Study: 28672319

Group type: EXPERIMENTAL
Intervention: Radiofrequency denervation combined with a standardized exercise program
Number of subjects: 681

Group type: COMPARATOR
Intervention: Standardized exercise program alone
Number of subjects: 681
Study: 25781025

Group type: EXPERIMENTAL
Intervention: Intravenous Zoledronic Acid (ZA), 2 doses, 3 weeks apart
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 23674934

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 21108032

Group type: EXPERIMENTAL
Intervention: Directive e-coach support
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nondirective e-coach support
Number of subjects: 104

Group type: COMPARATOR
Intervention: Minimal support
Number of subjects: 104
Study: 19242921

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for breast cancer patients over 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention for breast cancer patients
Number of subjects: 0
Study: 17270336

Group type: COMPARATOR
Intervention: Semi-automatic defibrillation (AED)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Manual defibrillation (MED)
Number of subjects: 32
Study: 15197018

Group type: EXPERIMENTAL
Intervention: Low- to moderate-intensity aerobic exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (usual activity)
Number of subjects: 140
Study: 11485158

Group type: EXPERIMENTAL
Intervention: 0.6% GLA (borage oil)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.6% GLA, 0.3% DHA, 0.06% EPA (borage oil + fish oil low)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 0.6% GLA, 0.3% DHA, 0.2% EPA (borage oil + fish oil high)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 66
Study: 9858950

Group type: EXPERIMENTAL
Intervention: Retarded morphine (mean dosage: 49.2 +/- 28.4 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no further therapy)
Number of subjects: 20
Study: 8116539

Group type: EXPERIMENTAL
Intervention: 15 g native amylomaize (Hylon‐VII) three times a day for 7 days, containing 28 g type II resistant starch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dextrins as a placebo
Number of subjects: 19
Study: 3291491

Group type: EXPERIMENTAL
Intervention: 1.5 ml PG E2 endocervical application
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 3 mg intravaginal PG E2
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oxytocin sensitivity test
Number of subjects: 160

Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal tablets
Number of subjects: 160
Study: 31189698

Group type: EXPERIMENTAL
Intervention: Alternative RUTF
Number of subjects: 1270

Group type: COMPARATOR
Intervention: Standard RUTF
Number of subjects: 1270
Study: 25300225

Group type: EXPERIMENTAL
Intervention: Food-only dietary energy density (ED)
Number of subjects: 172
Study: 23070146

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg twice a day for 3 days, followed by nilotinib 400 mg on Day 4 (famotidine given 2 h after nilotinib)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Antacid suspension 20 mL given 2 h before nilotinib 400 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Antacid suspension 20 mL given 2 h after nilotinib 400 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nilotinib 400 mg alone
Number of subjects: 52
Study: 20699330

Group type: EXPERIMENTAL
Intervention: Orally administered chemotherapy
Number of subjects: 99
Study: 19097705

Group type: EXPERIMENTAL
Intervention: TOT-AL online measure of past week alcohol consumption
Number of subjects: 0
Study: 16760903

Group type: EXPERIMENTAL
Intervention: Electrolyzed-reduced water (ERW) treatment for 6 months
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vitamin C treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Vitamin E-coated dialyzer treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 43
Study: 15205236

Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Tisseel Duo Quick)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Absorbable sutures (7‐0 Vicryl Rapid)
Number of subjects: 43
Study: 11320367

Group type: EXPERIMENTAL
Intervention: Inappropriate left ventricular hypertrophy (iLVH)
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: Concentric iLVH
Number of subjects: 659

Group type: COMPARATOR
Intervention: Concentric aLVH
Number of subjects: 659

Group type: COMPARATOR
Intervention: Eccentric aLVH
Number of subjects: 659

Group type: EXPERIMENTAL
Intervention: All groups (iLVH and aLVH)
Number of subjects: 659
Study: 9227725

Group type: EXPERIMENTAL
Intervention: Short wave diathermy for 25 minutes each day (n = 11)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Observation with bed rest (n = 11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Observation with bed rest
Number of subjects: 22
Study: 8260445

Group type: EXPERIMENTAL
Intervention: Neuroleptic withdrawal (haloperidol)
Number of subjects: 15
Study: 2888942

Group type: EXPERIMENTAL
Intervention: Captopril alone
Number of subjects: 14

Group type: COMPARATOR
Intervention: Frusemide plus amiloride
Number of subjects: 14
Study: 29144182

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Hartmann's solution (HS)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Plasma-Lyte 148 (PL) and Hartmann's solution (HS)
Number of subjects: 50
Study: 26850941

Group type: EXPERIMENTAL
Intervention: HPV self-sampling
Number of subjects: 8160

Group type: COMPARATOR
Intervention: Pap test reminders (Control)
Number of subjects: 8160
Study: 23868538

Group type: EXPERIMENTAL
Intervention: Volume Guarantee (VG) ventilation (Vt=5 mL/kg, PEEP=5 cmH2O)
Number of subjects: 25

Group type: COMPARATOR
Intervention: High Frequency Oscillatory Ventilation (HFOV)
Number of subjects: 25
Study: 22267455

Group type: EXPERIMENTAL
Intervention: Biaxial microincision (B-MICS)
Number of subjects: 42
Study: 20346539

Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 18551076

Group type: EXPERIMENTAL
Intervention: BRANDS allocation scheme
Number of subjects: 40

Group type: COMPARATOR
Intervention: UK National Allocation Scheme (NAS)
Number of subjects: 40
Study: 15946978

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 907

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 907